Martek Biosciences Corporation has posted a fall in half-year profits thanks to rising operating expenses.
Go deeper with GlobalData
The US firm, the company behind life’sDHA, recorded net income of US$7.6m for the six months to 30 April, down from $125.7m a year earlier.
The drop in profits came despite a rise in turnover. Sales reached $146.9m, up from $133.1m a year earlier.
CEO Steve Dubin expects sales and margins to rise in the second half of the year. “While Martek’s year-to-date earnings per share are currently below prior year levels, I expect Martek’s higher revenues and gross margin improvement in the second half of the year to generate full year earnings that exceed 2006 results,” Dubin said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
